de Divitiis O, Petitto M, Di Somma S, Galderisi M, Villari B, Santomauro M, Fazio S
Arzneimittelforschung. 1985;35(4):727-9.
The effectiveness and tolerability of nitrendipine (Bay e 5009) and atenolol in the treatment of mild or moderate arterial hypertension in monotherapy and in association were evaluated in a randomized double-blind study. The drugs were administered once daily at the dose of 20 mg for nitrendipine and 100 mg for atenolol. The trial consisted in two phases of monotherapy and of a combined regimen phase, whose sequence was randomly established; tablets were administered according to a double-dummy design. The results were evaluated according to the criteria of the Hypertension Detection and Follow-up Program Cooperative Group. 5/20 patients were considered "responders" after atenolol treatment, 4/20 after nitrendipine alone, and 14/20 after combined therapy. Side effects resulted mild in severity, and their incidence was lower during the association phase. The combination of atenolol and nitrendipine appears to improve the effectiveness and acceptability of both drugs.
在一项随机双盲研究中,评估了尼群地平(拜耳e 5009)和阿替洛尔单药治疗及联合治疗轻度或中度动脉高血压的有效性和耐受性。药物每日服用一次,尼群地平剂量为20毫克,阿替洛尔剂量为100毫克。试验包括两个单药治疗阶段和一个联合用药阶段,其顺序随机确定;片剂根据双盲设计给药。结果根据高血压检测与随访项目合作组的标准进行评估。阿替洛尔治疗后,20名患者中有5名被视为“反应者”,单独使用尼群地平治疗后有4名,联合治疗后有14名。副作用严重程度较轻,在联合治疗阶段其发生率较低。阿替洛尔和尼群地平联合使用似乎提高了两种药物的有效性和可接受性